Meeting
2017 ASCO Annual Meeting
A phase 1b, open label, single institution trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Authors
Ankit Madan
University of Alabama, Hoover, AL
Ankit Madan , Benjamin Scott Jones , Ravi Kumar Paluri , Mary Jerome , Debi Miley , Francisco Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02835833
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2614)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2614
Abstract #
TPS2614
Poster Bd #
97a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
First Author: Ravi Kumar Paluri
Poster
2013 ASCO Annual Meeting
Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
First Author: Nasser H. Hanna
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao
Poster
2016 ASCO Annual Meeting
Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.
First Author: Sara Michele Federico